Floxuridine (FUDR) Market Size, Share, and Trends Analysis Report, By Application (Lung Cancer, Gastrointestinal Cancer, Breast Cancer, and Liver Cancer), By End-user (Hospitals, Speciality Clinics, and Others), Forecast (2022-2028)

The global floxuridine (FUDR) market is anticipated to grow at a considerable CAGR during the forecast period (2022-2028). FUDR is an oncology drug used in chemotherapy for the treatment of several types of cancers, including liver cancer, lung cancer, stomach cancer, and breast cancer. The major factor attributing to the growth of the global FUDR market includes the rising prevalence of stomach cancer and liver cancer globally. According to the WHO, stomach cancer is the fifth-highest prevalent type of cancer globally, whose 1.1 million new cases were registered in 2020 and 768.8 thousand mortalities were caused due to this disease. Furthermore, liver cancer is the sixth-highly prevalent type of cancer globally, 905.7 thousand new cases were registered in 2020 and 830.2 thousand mortalities were caused. Thus, boosting the demand for FUDR for their treatment.

In addition, the increasing cases of breast cancer globally are also contributing to the growth of the global FUDR market. According to the report published by the World Health Organization (WHO), around 2.3 million women were diagnosed with breast cancer globally in 2020 with a mortality of around 6,85,000 women. The report also describes that at the end of 2020, around 7.8 million women are living with breast cancer across the globe.

Some of the major players in the market include Teva Pharmaceuticals Industries Ltd., Viatris Inc., F. Hoffmann-La Roche Ltd., DSM Nutritional Products AG, and Hikma Pharmaceuticals PLC, among others. These market players are also contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, to stay competitive in the market.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Application
  • By End-user
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Teva Pharmaceuticals Industries Ltd., Viatris Inc., F. Hoffmann-La Roche Ltd., DSM Nutritional Products AG, and Hikma Pharmaceuticals PLC, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global FUDR  Market Report by Segment

By Application

• Liver Cancer
• Gastrointestinal Cancer
• Breast Cancer
• Lung Cancer

By End-user

• Hospitals
• Speciality Clinics
• Others

Global FUDR  Market Report by Region

North America

• The United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa